Document is current
Any future updates will be listed below
-
Authors
Ourailidis, Iordanis https://orcid.org/0000-0001-6783-5617
Stögbauer, Fabian
Zhou, Yuxiang
Beck, Susanne https://orcid.org/0000-0002-2652-8722
Romanovsky, Eva
Eckert, Stephan
Wollenberg, Barbara
Wirth, Markus
Steiger, Katja https://orcid.org/0000-0002-7269-5433
Kuster, Bernhard
Gires, Olivier https://orcid.org/0000-0002-2292-7064
Stenzinger, Albrecht https://orcid.org/0000-0003-1001-103X
Schirmacher, Peter
Weichert, Wilko
Kuhn, Peer-Hendrik
Boxberg, Melanie
Budczies, Jan https://orcid.org/0000-0002-6668-5327
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (70113976, 70113973)
- License Information
-
More Information
Article History
Received: 15 August 2024
Accepted: 25 February 2025
First Online: 13 March 2025
Competing interests
: Katja Steiger is a member of the advisory board of TRIMT GmbH. Albrecht Stenzinger has received advisory boards from Agilent, Aignostics, Amgen, Astra Zeneca, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Qlucore, Roche, Seagen, Takeda, Thermo Fisher, and grants from Bayer, BMS, Chugai, Incyte, outside the submitted work. Jan Budczies reports grants from German Cancer Aid and consulting from MSD, outside the submitted work. The remaining authors declare no competing interests.
